© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Patient Care Editorial Staff
Articles
FDA Approves Neffy 1 mg Epinephrine Nasal Spray, Only Needle-Free Treatment for Patients Weighing Less Than 30 kg
March 06, 2025
The FDA approval of neffy 1 mg follows the earlier approval of the 5 mg version in August 2024.
Measles Outbreak Explained: Disease History, Vaccine Breakthrough and 2025 Resurgence
February 27, 2025
The 2025 measles outbreak in Texas has reignited discussion surrounding vaccine-preventable diseases and the importance of maintaining high immunization rates.
New neffy (epinephrine nasal spray) Data To Be Shared in 9 Presentations at 2025 AAAAI
February 26, 2025
Data on the epinephrine nasal spray will include findings from an efficacy study comparing anaphylaxis symptoms during oral food challenge, according to ARS.
Arcutis Announces Positive Phase 3 Data on Roflumilast Cream 0.05% for Atopic Dermatitis in Young Children
February 24, 2025
Investigators reported that roflumilast cream 0.05% significantly reduced AD severity as early as Week 1, with a notable effect on pruritus seen in as little as 24 hours.
FDA Authorizes Aptitude Metrix COVID/Flu Multiplex Molecular Test for Home and Point-of-Care Use
February 24, 2025
The Metrix COVID/Flu molecular test detects and differentiates SARS-CoV-2, influenza A, and influenza B in approximately 20 minutes.
FDA Approves Expanded Use for Sublocade for Opioid Use Disorder
February 24, 2025
These label changes to Sublocade from Indivior mark a significant advancement in the management of moderate to severe opioid use disorder.
FDA Clears IND for Alphyn’s Zabalafin Hydrogel for Atopic Dermatitis
February 20, 2025
The clearance enables Alphyn to initiate global phase 2b clinical trials, which are anticipated to begin in the first quarter of 2025.
FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes
February 14, 2025
Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.
Cannabis Use Disorder: FDA Grants Fast Track Status to Investigational Agent PP-01
February 13, 2025
The development comes at a time when cannabis use disorder has risen steadily in the United States.
5 Days in Hawaii: The Winter Clinical Hawaii Dermatology Conference
February 13, 2025
The Winter Clinical Hawaii Dermatology Conference will kick off on the Big Island on February 14th. Check out the agenda and the option to attend virtually.